Compare ProShares Ultra QQQ ETF (QLD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs 10X Genomics Inc — how do they compare? ProShares Ultra QQQ ETF trades at $87.85, while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| QLD | TXG | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $47.20 |
52-Week Low | $57.16 | $11.34 |
Market Cap | — | $5.48B |
Enterprise Value | — | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD, the ProShares Ultra QQQ ETF, trades at $86.06, up 0.17% on the day, with a bearish technical signal driven by moving averages. The ETF, which provides 2x daily leveraged exposure to the Nasdaq-100 index, has delivered over 10,000% total return since inception, demonstrating powerful long-term compounding. Recent news highlights its role in tech-focused strategies amid a Nasdaq comeback, though leveraged structure amplifies volatility.
Outlook is mixed: technicals suggest near-term caution, but long-term growth potential remains tied to tech sector performance. Key risks include daily rebalancing effects in volatile markets and significant drawdowns, as seen historically. Investors should weigh leveraged benefits against inherent volatility and holding period considerations.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
